A gain-of-function study of amelioration of pentylenetetrazole-induced seizures by endogenous prostaglandin D2

Neurosci Lett. 2018 Nov 1:686:140-144. doi: 10.1016/j.neulet.2018.09.011. Epub 2018 Sep 7.

Abstract

We previously showed that knockout mice of hematopoietic prostaglandin (PG) D synthase (H-PGDS) produce less PGD2 to exacerbate pentylenetetrazole (PTZ)-induced seizures. Here, we adopted a gain-of-function strategy and used transgenic mice that over-express human H-PGDS enzyme, to elucidate the role of overproduction of endogenous PGD2 in PTZ-induced seizures. H-PGDS-transgenic mice showed the elevated level of a urinary metabolite of PGD2, tetranor-PGDM, 3.3- and 2.8-fold higher than the wild-type littermates under the basal condition and after the PTZ administration, respectively, without significantly changing the urinary concentration of a PGE2-metabolite, tetranor-PGE2. The intensity of PTZ-induced seizures was decreased in H-PGDS-transgenic mice as evident by the increased seizure onset latency, and a decrease in total duration of generalized tonic-clonic seizures and a total number of EEG seizure spikes during the postictal period (84 s, 17 s, and 5.3/min, respectively), as compared to wild-type mice (53 s, 24 s, and 12.6/min, respectively). These results indicate that overproduction of endogenous PGD2 decreased PTZ-induces seizures.

Keywords: Convulsion; Electrographic seizures; H-PGDS transgenic mice; Postictal EEG depression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects*
  • Gain of Function Mutation / drug effects*
  • Humans
  • Mice, Knockout
  • Mice, Transgenic
  • Pentylenetetrazole / pharmacology*
  • Prostaglandin D2 / analogs & derivatives*
  • Prostaglandin D2 / pharmacology
  • Seizures / drug therapy*
  • Seizures / physiopathology

Substances

  • 11,15-dioxo-9-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid
  • Prostaglandin D2
  • Pentylenetetrazole